The Michigan Radiation Oncology Quality Consortium (MROQC) is a comprehensive clinical and physics database to support quality improvement throughout Michigan. MROQC was established in 2011, through the generous support from Blue Cross Blue Shield of Michigan and Blue Care Network as part of the BCBSM Value Partnerships Program.
MROQC has created a comprehensive clinical and physics data registry of patients receiving radiation treatment for breast, lung and prostate cancers and bone metastases. The MROQC registry includes both patient-reported outcomes and physician assessments of toxicity as well as data on radiation treatment delivery and dose.
The overall aims of the collaborative include, among others, to determine the most appropriate use of intensity modulated radiation therapy (IMRT) for breast and lung cancer patients as well to establish and disseminate best practice guidelines that enable radiation oncology practitioners to optimize the delivery of cost-effective care. These guidelines provide for reduction in radiation treatment times and costs of radiation treatment for breast, lung, prostate cancers and for cancer that has spread to the bones while enhancing the overall quality, value and outcomes for patients receiving radiation therapy in Michigan.
